Superior Survival for Asian Men With Prostate Cancer
Superior median overall survival and prostate cancer-specific mortality in de novo metastatic PCa
TUESDAY, Jan. 24, 2017 (HealthDay News) -- For men with distant, de novo, metastatic prostate cancer (PCa), Asian ethnicity is associated with superior median overall survival (OS) and PCa-specific mortality (PCSM), according to a study published online Jan. 5 in Cancer.
Brandon Bernard, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues identified men with distant, de novo, metastatic PCa from 2004 to 2012 from the Surveillance, Epidemiology, and End Results (SEER) registry. For each race the authors determined patterns of presentation, OS, and PCSM. To assess outcomes of androgen-deprivation therapy (ADT) and ADT plus docetaxel for each race they retrospectively reviewed E3805 clinical trial data.
The researchers found that of all PCa diagnoses, distant, de novo, metastatic disease was diagnosed in 4.2, 5.8, 5.7, 5.5, and 8.8 percent of non-Hispanic whites, Hispanic whites, blacks, Asians/Pacific Islanders, and American Indians/Alaska Natives, respectively, in SEER. Median OS differed by race, with Asian men having superior OS compared to men of other races (30 versus 24 to 25 months; P < 0.001). Compared with other races, Asian men also had superior median PCSM (54 versus 35 to 40 months; P < 0.001). Chemohormonal therapy in E3805 correlated with a median OS of 58.1 and 57.6 months in non-Hispanic whites and blacks, respectively; there were few Asian participants in E3805.
"Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race," the authors write.